Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms RSS Feed RSS Feeds


Press Release

Skin & Skin Structure Infections (SSSI) Caused By Bacteria - Pipeline Insight, 2018 -

Research and Markets
Posted on: 14 Dec 18

The "Skin And Skin Structure Infections (SSSI) Caused By Bacteria - Pipeline Insight, 2018" drug pipelines has been added to's offering.

This report offers comprehensive Insight of the pipeline (under development) therapeutics scenario and growth prospects across Skin & Skin Structure Infections (SSSI) Caused by Bacteria development.

The report provides detailed coverage of the pipeline landscape for this mechanism of action, equipped with data from multiple sources with complete pipeline analysis by developmental stage, associated indications, route of administration and molecule type.

Pipeline therapeutics development coverage provides descriptive product profiles including (but not limited to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details.

Scope of the Report

  • The report provides a snapshot of the pipeline development
  • The report covers pipeline activity across the complete product development cycle i.e. clinical, pre-clinical and discovery stages
  • The report provides pipeline product profiles which includes product description, developmental activities, licensors & collaborators and chemical information
  • Provides pipeline assessment by monotherapy and combination therapy products, stage of development, route of administration and molecule type
  • The report also covers dormant and discontinued pipeline projects

Topics Covered

1. Report Introduction

2. Skin & Skin Structure Infections (SSSI) Caused by Bacteria Overview

3. Pipeline Therapeutics

4. Comparative Analysis

5. Products in Clinical Stage

6. Products in Pre-Clinical and Discovery Stage

7. Therapeutic Assessment

8. Inactive Products

Companies Featured

  • GlaxoSmithKline
  • Melinta Therapeutics
  • Paratek Pharmaceuticals
  • Debiopharm International
  • MerLion Pharmaceuticals
  • Nabriva Therapeutics
  • Cempra
  • Cellceutix Corporation
  • Tetraphase Pharmaceuticals
  • Durata Therapeutics

For more information about this drug pipelines report visit

View source version on

Business Wire

Last updated on: 14/12/2018

Site Map | Privacy & Security | Cookies | Terms and Conditions is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.